Sage Journals: Discover world-class research

Abstract

Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease of the central nervous system. It affects young people, and a considerable percentage of patients need the help of a wheelchair in 15 years of evolution. Currently, there is not a specific technique for the diagnosis of MS. The detection of oligoclonal IgG bands (OIgGBs) is the most sensitive assay for it, but it is not standardizable, only reference laboratories develop it, and uses cerebrospinal fluid. To obtain this sample, a lumbar puncture is necessary, an invasive proceeding with important side effects. It is important to develop and implement standard assays to obtain a rapid diagnosis because the earlier the treatment, the better the evolution of the disease. There are numerous modifying disease therapies, which delay the progression of the disease, but they have important side effects, and a considerable percentage of patients give up the treatment. In addition, around 40% of MS patients do not respond to the therapy and the disease progresses. Numerous researches have been focused on the characterization of predictive biomarkers of response to treatment, in order to help physicians to decide when to change to a second-line treatment, and then the best therapeutic option. Here, we review the new biomarkers for the diagnosis and response to treatment in MS. We draw attention in a new assay, the detection of serum IgM to phosphatidylcholine, that showed a similar sensitivity as OIgGBs and predicts the response to disease modifying treatments.

Keywords

biomarkers diagnosis prognosis IgM interferon-β multiple sclerosis phosphatidylcholine Tysabri®

Introduction

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, characterized by demyelination and axonal loss.¹ It is estimated that more than 2.8 million people are diagnosed around the world, and the incidence is increasing.² It usually presents between the third and fourth decade of the life and has a high social impact.^3–5

The ethology is unknow,⁶ and it is hypothesized that autoreactive lymphocytes migrate to the central nervous and would be the responsible of the demyelinating plaques.⁷

The lesions can affect all the areas of the central nervous system, the histopathology is different among patients,^8–11 and for these reasons, the clinical manifestations and the evolution of the patients are very variable.^12,13

Consequently, the diagnosis is complex, and it is based on criteria diagnosis which include the assertion of symptoms related with demyelination and laboratory test.^14–16

Regarding this, the hallmark of the disease is the presence of intrathecal IgG synthesis,^14,17–19 demonstrating the aberrant activation of B-lymphocytes in the central nervous system. Intrathecal IgG synthesis can be observed in approximately 70% of MS patients using quantitative methods.¹⁷ These assays are based on the quantification of IgG and albumin in the cerebrospinal fluid (CSF) and serum using nephelometry.²⁰

Nevertheless, the sensitivity of these procedures is lower compared to qualitative techniques. The later, based on isoelectric focusing and immunodetection assays demonstrated the presence of oligoclonal bands in approximately 90% of MS patients.^18,21–23

Currently, the detection of oligoclonal IgG bands (OIgGBs) is the gold standard for the diagnosis of MS.^{14,17,21–24} The pattern of OIgGBs is variable among MS patients, but it remains unchanged in the same patient.^23,25,26 Moreover, the IgG obtained extracted from autopsy brain plaques also showed and oligoclonal pattern.²⁷

These evidences indicate that different antigens can be involved in the activation of the humoral immune response in MS patients. It was observed that IgG from the CSF target myelin and neuron antigens, such as, myelin basic protein,^28–31 myelin oligodendrocyte glycoprotein,³² proteolipid lipoprotein,³¹ myelin-associated glycoprotein,³³ glycolipids, fatty acids, and neurofilaments.³⁴ Other authors demonstrated that antibodies from MS patients bind to oligodendroglial and neuronal cell-lines.³⁵ Recently, is was demonstrated that OgIgGBs target debris.²¹ These data indicate that IgG also plays a pathogenic role.

Unfortunately, the detection of OIgGBs is cumbersome and the sensitivity between laboratories is very variable.^36–38 Moreover, it is necessary to perform a lumbar puncture to obtain CSF, an invasive technique with important side effects.

An ideal biomarker must be specific of the disease, safe for the patient, easy to detect, and in the best case, the proceeding must be noninvasive. Blood samples fulfill these requirements, the obtention of the sample is safe, quick, and easy, and it could be performed at different timepoints.³⁹

Regarding this, the presence in blood of B cell against brain antigens is related to disease relapses in MS.⁴⁰ The number of CD5+ B lymphocytes are also related with the activity of the disease.⁴¹ These cells produce natural antibodies, most of which recognize lipids,^42–44 and it was described that serum antibodies to this antigens correlate with the damage of the brain tissue.⁴⁵ These data indicate that peripheral lymphocytes play a main role in myelin destruction and are in agreement with the mechanisms occurring in the central nervous during the progressive phase of MS.^7,46

High levels of S100β in serum are detected during exacerbations in remittent recurrent MS patients.^47,48 There is a correlation between the levels of neurofilament light chain (NfL) in CSF and those observed in serum.^6,49,50 The levels of NfL associate with the activity of the disease,⁵¹ number of lesions observed in magnetic resonance imaging (MRI)^50,52–54 and disability.⁵⁵ However, other authors indicate that there is no correlation between the levels of NfL and long-term disability or number of relapses overtime.⁵²

In summary, there is not a universally accepted serum biomarker for the diagnosis or predicts the prognosis of MS up today. Therefore, it is necessary to determine new diagnosis and prognosis biomarkers in MS.

Here, we demonstrate that serum IgM to phosphatidylcholine (IgMPC) is a new diagnosis biomarker and also predicts the response to disease modifying therapies.

Antibodies to lipids are a main characteristic of MS patients

Myelin consists mainly of lipids, being the most abundant, cholesterol, PC, sphingomyelin, cerebrosides, and sulfatide.^56,57 Ganglioside (GD) are also main components of myelin and axolemma, especially at the node of Ranvier.^58,59 Moreover, glycolipid composition is particular of every glial cell subset, GD2 is characteristic of mature oligodendrocytes, and GD1and GD3 are present on their precursors.⁶⁰

Consequently, numerous researchers have been working to develop new diagnosis techniques and to detect antibodies to lipids in MS.

Enzyme-linked immunosorbent assays (ELISAs) demonstrated the high prevalence of antibodies to lipids in serum and CSF samples from MS patients (Table 1). They recognize a broad spectrum of gangliosides⁶¹ (aGM1,⁶² GM1,^{37,58,62–66} GM2³⁷ GM3,^37,63,64 GM4,³⁷ GD1a,^{58,62–64,67} GD1b,^37,58,63 GD2,^37,67 GD3,^37,63,64,67 GT1a,³⁷ and GTB³⁷), sulfatide,^{37,58,64,68,69} cerebrosides,^61,68,70 phosphatidylinositol,⁶⁸ cardiolipin,^71,72 and cholesterol.⁶⁸

Table 1.

Analysis of the reactivity to lipids in CSF and serum samples from MS patients.

Author	Antigen and positive patients (%)	Lipid positive MS patients (%)
Acarin et al.⁶² (S)	aGM1 (24% IgG/IgM); GM1 (38% IgG/IgM); GD1a 33% (IgG/IgM)	48% of Total 36% RR IgG/IgM	33% SP IgG/IgM	100% PP IgG/IgM
Sadatipour et al.⁶³ (S)	GM1; GM3; GD1a, GD1b; GD3	2.9% RR IgG/IgM/IgA/IgD	42.9% SP	56% PP
Mata et al.⁵⁸ (S)	GM1 (10% IgG); GD1a (23% IgG; 10% IgM); GD1b (13% IgG; 6% IgM); Sulfatides (3% IgG; 7% IgM); Cardiolipin (3% IgG)	50% MALIGNANT IgG	6% BENIGN IgG
(CSF)	GM1 (7% IgM); GD1a (13%, IgG); Sulfatides (3% IgG, 16% IgM); Cardiolipin (20% IgM)	26% MALIGNANT IgG	6% BENIGN IgG
Giovannoni et al.⁶⁴ (S)	GM1; GM3; GD1a; GD3; GT1; GQ1; Sulfatides
Marconi et al.⁶⁷ (S)	GD1a; GD2; GD3	30% of Total (IgM)24.2% RR GD2+	50% SP GD2+	26.7% GD2+
Menge et al.⁷⁰ (S)	Galactocerebroside	<10% CIS	40% RR IgG	26.7% SP IgG	<10% PP IgG
Jurewicz et al.⁶⁸ (S)	Sulfatides; Galactocerebroside; Phosphatidylinositol; cholesterol (IgG/IgM)	RR
Ilyas et al.⁶⁹ (CSF)	Sulfatides	19.74% of Total IgG/IgM15% RR	30% SP	14% PP
Ivanova et al.³⁷ (S)	GM1 (10% IgG/IgM); GM2; GM3; GM4; GD1a; GD1b; GD2; GD3; GT1a; GT1b; GQ1b; Sulfatides (33.3% IgG/IgM)	42.3% Ig/IgM38.1% RR	51.4% SP
Colaço et al.⁷¹(S)	Cardiolipin (29.4% IgM)	29.4% IgM
Lolli et al.⁷² (S)	Cardiolipin	2% IgG; 7% IgM
(CSF)		5% IgG; 7% IgA, 9% IgM
Mathiesen et al.⁶⁵ (CSF)	GM1 (16.7% IgG)	16.7% IgG
Marchiori et al.⁶¹(CSF)	Gangliosides (19.2% IgG; 7.7% IgM); Cardiolipin (46.2% IgG; 6.0% IgM); Galactocerebrosides (17.7% IgG; 11.8% IgM)
Bech et al.⁶⁶ (S)	GM1 IgM
Sádaba et al.⁷³ (S)	Phosphatidylcholine (IgM)	88.2% CIS; 88.7% RR	58.0% SP	59.5% PP	11.1% BENIGN

aGM1, asialoganglioside; CIS, Clinically isolated syndrome; CSF, cerebrospinal fluid; GD, ganglioside D; GM, ganglioside M; GT, ganglioside T; GQ, ganglioside M; MS, Multiple sclerosis; PP, Primary progressive; RR, Relapsing-remitting; S, serum; SP, Secondary progressive.

Interestingly, new microarray techniques showed the presence in the CSF of antibodies to lipids up to 60% of MS patients, being sulfatides the antigens recognized in most cases.^74–76

Nevertheless, the incidence of the antibodies to this lipids is lower compared with that of the OIgGBs,^14,17,18,77 and these techniques are not currently used in the diagnosis of MS.⁷³

Serum antibodies to PC are a diagnostic marker in MS

We developed a high sensitive ELISA to detect antibodies to lipids. We overcame the difficulties regarding the antigen solubility, accessibility of reactive groups, and the requirement of auxiliary lipids.

This assay demonstrated the upregulated concentration of IgMPC in serum samples from MS patients. More interesting, almost 90% of MS patients in the first stages of the disease, clinical isolated syndrome (CIS) or relapsing remitting MS, had serum IgMPC. However, a minimum percentage of benign patients and control group showed serum IgMPC⁷³ (Figure 1).

Figure 1.

Percentage of positives (white bars) or negatives (squared bars) for IgMPC in MS patients in the first stages of the disease (CIS or RR) or benign form and control group. The percentage of positives for IgMPC was higher in patients in the first stages of the disease (88.5%) than in patients with the benign form (11.1%) and control group (25%)

The sensitivity of our new assay is similar to the best obtained using the detection of OIgGBs, the gold standard for the diagnostic of MS at the moment. In other words, the detection of IgMPC in serum samples is a diagnostic marker in this disease and has numerous advantages compared with the detection of OIgGBs.^73,78 It is an easily reproducible technique; it can be automatable, and it does not use CSF.

Antibodies to lipids are a prognosis marker

Different reports demonstrated the higher prevalence of antibodies to gangliosides in the progressive forms than in the first stages of the disease.^62,63 In this line, it was also published that a significant percentage of MS patients with malignant course have IgG to gangliosides, sulfatides, and cardiolipin in serum and CSF.⁵⁸ However, other authors did not find this correlation, and the role of the antibodies to these antigens as prognosis biomarker remains unclear.

Intrathecal IgM synthesis correlates with a severe disease course of the disease.^79–82

The most sensitive assay to detect intrathecal IgM synthesis⁸³ demonstrated the presence of oligoclonal IgM bands (OIgMBs) in CSF in approximately 45% of the MS patients.⁸⁴ Patients with OgIgMBs predict the conversion to clinically defined MS and a rapid progression. We observed that these immunoglobulins recognized phospholipids and glycolipids, being PC the antigen recognized in most cases.⁸⁵ Patients with OIgMBs to lipids have a poor prognosis, with higher rate of relapses, faster increase of disability, remarkable brain atrophy and lesion load, and early development of the secondary progressive phase.^85–90 Currently, the detection of OIgMBs to lipids is the most sensitive biomarker for the prognosis of MS.^91,92

Nevertheless, the sensitivity to detected IgM in CSF varies among laboratories,⁹² as described for the detection of OIgGBs, and some authors did not observe relation between the presence of OIgMBs and the progression of the disease.^93–95

However, using our reproducible and high sensitive ELISA, we observed that most of the benign MS patients did not have serum IgMPC.⁷⁷

Antibodies to lipids are pathogenic

The increased concentration of IgM in CSF is related with the MRI lesion load,⁷⁹ and the presence of antibodies to lipids in CSF⁸⁷ and serum⁴⁵ correlates with brain atrophy.

The presence of OIgMBs in MS patients correlate with increased percentages of B1-lymphocytes in CSF and blood,^85,88,96 the B cells subset producer of antibodies to lipids. Moreover, the increased number of B1-lymphocytes in peripheral blood predicts the conversion to MS in those patients with an unclear diagnosis,⁴¹ demonstrating the pathogenic role of this cells.

The histological studies also demonstrated the pathological role of antibodies to lipids and B cells. We observed in brain samples from MS patients, IgM deposits colocalizing with complement cascade factors, which in turn could mediate the lysis of oligodendrocytes and axons, and the phagocytosis of debris by activated macrophages.⁹⁷ In fact, IgM deposits colocalize with oligodendrocyte and axonal damage.⁹⁸ In this line, other authors also demonstrated that antibodies are the main characteristic of new forming lesions.⁹⁹ Corroborating the data obtained in CSF and serum, we also observed that the activity of the lesions is related with the number of B cells and plasma cells in the perivascular space and meninges.⁹⁸

Other authors demonstrated that IgM anti-sulfatide or anti-galactocerebroside from MS patients recognize oligodendrocytes and myelin, causing demyelination ‘in vitro’ and ‘in vivo’.¹⁰⁰

Moreover, immunization of experimental animals with lipids or antibodies to lipids causes the development of experimental autoimmune encephalomyelitis. These models demonstrated that antibodies are necessary to induce similar pathology to that observed in humans.^74,101–106

Antibodies to lipids predict the response to disease modifying treatments

Treatments do not cure the disease but delay the progression in most cases. Unfortunately, a considerable percentage of patients do not respond to the first-line therapies or suffer from important side effects.^107–109 Currently, the response or not to treatment is identified based on the occurrence of new relapses or the increase of disability. This is problematic because as the disease progress, patients do not recover completely the neurological function after the relapse. Thus, numerous researches aimed to characterize biomarkers of response to treatment, and thus, to develop personalized therapies, improving their effectiveness while minimizing adverse events.

Recently, we observed that the rapid decrease of serum IgMPC is a biomarker of response to interferon-β (Figure 2(a)). Most of responders to Rebif® (Merck) (83.3%) or Betaferon® (Bayer) (85.7%) showed a diminution of serum IgMPC after 6 months of treatment [Figure 2(b)].

Figure 2.

Levels of IgMPC before (B.T) and after (A.T) treatment in patients no responders (a) and responders (b) to interferon-β. (c) Percentage of patients showing a decrease of the levels of IgMPC after 6 months of treatment.

Some patients who did not respond to interferon-β were treated with natalizumab. We demonstrated that those with the highest levels of IgMPC responded subsequently to natalizumab.⁷⁸ This was expected because these patients have an aggressive course, with more relapses and faster increase of the disability, and they do not respond to first-line therapies.⁷⁸

Natalizumab prevents the migration of lymphocytes through the blood–brain barrier, but, as we and other groups demonstrated, there are resident immune cells in the central nervous system.^98,110,111 Regarding this, natalizumab does not eliminate completely the presence of OIgMBs in CSF,¹¹² that, as described above, could play a main role in the tissue damage.

To predict the response to first-line therapies and natalizumab is of great interest to initiate the treatment of natalizumab as soon as possible, and thus to avoid the migration to the central nervous system of lymphocytes and the progression of the disease.

Conclusions

The detection of serum IgMPC is of great utility for the rapid diagnosis of MS and thus to treat the patients earlier. The later avoids the progression of the disease, but a considerable percentage of patients do not respond to first or second-line therapies. The levels of serum IgMPC predict the response to interferon-β and natalizumab. Thus, the quantification of these immunoglobulins is of great interest to decide when to change to a second-line treatment and then, the best therapeutic option.

Footnotes

Acknowledgements

We thanks to Dra. Elena Urcelay and Dr. Roberto Álvarez-Lafuente for their contribution to previous studies

Declarations

ORCID iDs

Isabel Sánchez-Vera

Esther Escudero

Úrsula Muñoz

María C. Sádaba

References

Reich

Lucchinetti

Calabresi

. Multiple sclerosis. New Engl J Med 2018; 378: 169–180.

Walton

King

Rechtman

, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler 2020; 26: 1816–1821.

Pugliatti

Rosati

Carton

, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13: 700–722.

Nicholas

Heaven

Middleton

, et al. Personal and societal costs of multiple sclerosis in the UK: a population-based MS Registry study. Mult Scler J Exp Transl Clin 2020; 6: 2055217320901727.

Gbaguidi

Guillemin

Soudant

, et al. Age-period-cohort analysis of the incidence of multiple sclerosis over twenty years in Lorraine, France. Sci Rep 2022; 12: 1001.

Harris

Tuddenham

Sadiq

. Biomarkers of multiple sclerosis: current findings. Degener Neurol Neuromuscul Dis 2017; 7: 19–29.

Baecher-Allan

Kaskow

Weiner

. Multiple sclerosis: mechanisms and immunotherapy. Neuron 2018; 97: 742–768.

Lucchinetti

Brück

Parisi

, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707–717.

Lucchinetti

Brück

Rodriguez

, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259–274.

10.

Metz

Weigand

Popescu

, et al. Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol 2014; 75: 728–738.

11.

Lucchinetti

Popescu

Bunyan

, et al. Inflammatory cortical demyelination in early multiple sclerosis. New Engl J Med 2011; 365: 2188–2197.

12.

Disanto

Berlanga

Handel

, et al. Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. Autoimmune Dis 2010; 2011: 932351.

13.

Lassmann

Brück

Lucchinetti

. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115–121.

14.

Poser

Paty

Scheinberg

, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–231.

15.

McDonald

Compston

Edan

, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

16.

Thompson

Banwell

Barkhof

, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162–173.

17.

Andersson

Alvarez-Cermeño

Bernardi

, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994; 57: 897–902.

18.

Sádaba

González Porqué

Masjuan

, et al. An ultrasensitive method for the detection of oligoclonal IgG bands. J Immunol Methods 2004; 284: 141–145.

19.

Kabat

Moore

Landow

. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins 1. J Clin Investig 1942; 21: 571–577.

20.

Reiber

Peter

. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 2001; 184: 101–122.

21.

Winger

Zamvil

. Antibodies in multiple sclerosis oligoclonal bands target debris. Proc Natl Acad Sci USA 2016; 113: 7696–7698.

22.

Dobson

Ramagopalan

Davis

, et al. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013; 84: 909–914.

23.

Link

Huang

. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006; 180: 17–28.

24.

Mantero

Abate

Balgera

, et al. Clinical application of 2017 McDonald diagnostic criteria for multiple sclerosis. J Clin Neurol 2018; 14: 387–392.

25.

Walsh

Tourtellotte

. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med 1986; 163: 41–53.

26.

Pryce

Baker

. Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter? Multiple Scler Relat Disord 2018; 25: 131–137.

27.

Glynn

Gilbert

Newcombe

, et al. Analysis of immunoglobulin G in multiple sclerosis brain: quantitative and isoelectric focusing studies. Clin Exp Immunol 1982; 48: 102–110.

28.

Cross

Trotter

Lyons

. B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001; 112: 1–14.

29.

Cruz

Olsson

Ernerudh

, et al. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology 1987; 37: 1515–1519.

30.

Link

Baig

Olsson

, et al. Persistent anti-myelin basic protein IgG antibody response in multiple sclerosis cerebrospinal fluid. J Neuroimmunol 1990; 28: 237–248.

31.

Warren

Catz

. Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J Neurol Sci 1994; 121: 66–73.

32.

Xiao

Linington

Link

. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol 1991; 31: 91–96.

33.

Möller

Johnson

Brady

, et al. Antibodies to myelin-associated glycoprotein (MAG) in the cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 1989; 22: 55–61.

34.

Blauth

Soltys

Matschulat

, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants. Acta Neuropathol 2015; 130: 765–781.

35.

Nazir

Wiberg

Müller

, et al. Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines. Brain Commun 2023; 5: fcad164.

36.

Schäffler

Köpke

Winkler

, et al. Accuracy of diagnostic tests in multiple sclerosis–a systematic review. Acta Neurol Scand 2011; 124: 151–164.

37.

Ivanova

Zakharova

. Antibodies against myelin lipids in multiple sclerosis. Hum Physiol 2017; 43: 875–880.

38.

Olsson

Link

. Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch Neurol 1973; 28: 392–399.

39.

Ziemssen

Akgün

Brück

. Molecular biomarkers in multiple sclerosis. J Neuroinflammation 2019; 16: 272.

40.

Hohmann

Milles

Schinke

, et al. Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood. Acta Neuropathol Commun 2014; 2: 138.

41.

Villar

Espiño

Roldán

, et al. Increased peripheral blood CD5+ B cells predict earlier conversion to MS in high-risk clinically isolated syndromes. Mult Scler 2011; 17: 690–694.

42.

Grönwall

Vas

Silverman

. Protective roles of natural IgM antibodies. Front Immunol 2012; 3: 66.

43.

Grönwall

Silverman

. Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease. J Clin Immunol 2014; 34(Suppl. 1): S12–S21.

44.

Vas

Grönwall

Silverman

. Fundamental roles of the innate-like repertoire of natural antibodies in immune homeostasis. Front Immunol 2013; 4: 4.

45.

Bakshi

Yeste

Patel

, et al. Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016; 3: e200.

46.

Thompson

Baranzini

Geurts

, et al. Multiple sclerosis. Lancet 2018; 391: 1622–1636.

47.

Missler

Wandinger

Wiesmann

, et al. Acute exacerbation of multiple sclerosis increases plasma levels of S-100 protein. Acta Neurol Scand 1997; 96: 142–144.

48.

Rostasy

Withut

Pohl

, et al. Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. J Child Neurol 2005; 20: 822–825.

49.

Disanto

Barro

Benkert

, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017; 81: 857–870.

50.

Kuhle

Barro

Disanto

, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler 2016; 22: 1550–1559.

51.

Ljubisavljevic

Stojanovic

Basic

, et al. The validation study of neurofilament heavy chain and 8-hydroxy-2’-deoxyguanosine as plasma biomarkers of clinical/paraclinical activity in first and relapsing-remitting demyelination acute attacks. Neurotox Res 2016; 30: 530–538.

52.

Cantó

Barro

Zhao

, et al. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 Years. JAMA Neurol 2019; 76: 1359–1366.

53.

Akgün

Kretschmann

Haase

, et al. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurol Neuroimmunol Neuroinflamm 2019; 6: e555.

54.

Uher

Schaedelin

Srpova

, et al. Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurol Neuroimmunol Neuroinflamm 2020; 7: e714.

55.

Thebault

Abdoli

Fereshtehnejad

, et al. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep 2020; 10: 10381.

56.

O’Brien

Sampson

. Fatty acid and fatty aldehyde composition of the major brain lipids in normal human gray matter, white matter, and myelin. J Lipid Res 1965; 6: 545–551.

57.

Hayes

Ntambi

. Multiple sclerosis: lipids, lymphocytes, and vitamin D. Immunometabolism 2020; 2: e200019.

58.

Mata

Lolli

Soderstrom

, et al. Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. Mult Scler 1999; 5: 379–388.

59.

DeVries

Zetusky

Zmachinski

, et al. Lipid composition of axolemma-enriched fractions from human brains. J Lipid Res 1981; 22: 208–216.

60.

Marconi

De Toni

Lovato

, et al. Expression of gangliosides on glial and neuronal cells in normal and pathological adult human brain. J Neuroimmunol 2005; 170: 115–121.

61.

Marchiori

Dos Reis

Quevedo

, et al. Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barré syndrome and systemic lupus erythematosus. Arq Neuropsiquiatr 1990; 48: 465–468.

62.

Acarín

Río

Fernández

, et al. Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol Scand 1996; 93: 99–103.

63.

Sadatipour

Greer

Pender

. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44: 980–983.

64.

Giovannoni

Morris

Keir

. Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis. Ann Neurol 2000; 47: 684–685.

65.

Mathiesen

von Holst

Fredrikson

, et al. Total, anti-viral, and anti-myelin IgG subclass reactivity in inflammatory diseases of the central nervous system. J Neurol 1989; 236: 238–242.

66.

Bech

Jakobsen

Orntoft

. ELISA-type titertray assay of IgM anti-GM1 autoantibodies. Clin Chem 1994; 40: 1331–1334.

67.

Marconi

Acler

Lovato

, et al. Anti-GD2-like IgM autoreactivity in multiple sclerosis patients. Mult Scler 2006; 12: 302–308.

68.

Jurewicz

Domowicz

Galazka

, et al. Multiple sclerosis: presence of serum antibodies to lipids and predominance of cholesterol recognition. J Neurosci Res 2017; 95: 1984–1992.

69.

Ilyas

Chen

Cook

. Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol 2003; 139: 76–80.

70.

Menge

Lalive

von Büdingen

, et al. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005; 116: 453–459.

71.

Colaço

Scadding

Lockhart

. Anti-cardiolipin antibodies in neurological disorders: cross-reaction with anti-single stranded DNA activity. Clin Exp Immunol 1987; 68: 313–319.

72.

Lolli

Matá

Baruffi

, et al. Cerebrospinal fluid anti-cardiolipin antibodies in neurological diseases. Clin Immunol Immunopathol 1991; 59: 314–321.

73.

Sadaba

Rothhammer

Muñoz , et al. Serum antibodies to phosphatidylcholine in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2020; 7: e765.

74.

Brennan

Galban-Horcajo

Rinaldi

, et al. Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J Neuroimmunol 2011; 238: 87–95.

75.

Kanter

Narayana

, et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006; 12: 138–143.

76.

Yeste

Quintana

. Antigen microarrays for the study of autoimmune diseases. Clin Chem 2013; 59: 1036–1044.

77.

Villar

Masjuan

Sádaba

, et al. Early differential diagnosis of multiple sclerosis using a new oligoclonal band test. Arch Neurol 2005; 62: 574–577.

78.

Muñoz

Sebal

Escudero

, et al. Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β. Sci Rep 2022; 12: 13357.

79.

Jongen

Lycklama

Nijeholt

Lamers

, et al. Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis. Eur Neurol 2007; 58: 90–95.

80.

Perini

Ranzato

Calabrese

, et al. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 953–955.

81.

Ferraro

Simone

Bedin

, et al. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome. J Neuroimmunol 2013; 257: 76–81.

82.

Ferraro

Galli

Vitetta

, et al. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: association with oligoclonal IgM bands and prediction of multiple sclerosis diagnosis. J Neuroimmunol 2015; 283: 64–69.

83.

Villar

González-Porqué

Masjuán

, et al. A sensitive and reproducible method for the detection of oligoclonal IgM bands. J Immunol Methods 2001; 258: 151–155.

84.

Villar

Masjuan

Gonzalez-Porque

, et al. Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology 2002; 58: 824–826.

85.

Villar

Sádaba

Roldán

, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Investig 2005; 115: 187–194.

86.

Espiño

Abraira

Arroyo

, et al. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. Clin Chim Acta 2015; 438: 67–69.

87.

Magraner

Bosca

Simó-Castelló

, et al. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiol 2012; 54: 5–12.

88.

Villar

García-Barragán

Espiño

, et al. Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult Scler 2008; 14: 183–187.

89.

Monreal

Sainz de la Maza

Costa-Frossard

, et al. Predicting aggressive multiple sclerosis with intrathecal IgM synthesis among patients with a clinically isolated syndrome. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1047.

90.

Thangarajh

G-r

. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis . Mult Scler 2008; 14: 1208–1213.

91.

Villar

Masterman

Casanova

, et al. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. J Neuroimmunol 2009; 211: 101–104.

92.

Mailand

Frederiksen

. Intrathecal IgM as a prognostic marker in multiple sclerosis. Mol Diagn Ther 2020; 24: 263–277.

93.

Durante

Zaaraoui

Rico

, et al. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler 2012; 18: 587–591.

94.

Abdelhak

Hottenrott

Mayer

, et al. CSF profile in primary progressive multiple sclerosis: re-exploring the basics. PLoS One 2017; 12: e0182647.

95.

Frau

Villar

Sardu

, et al. Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? J Neurol 2018; 265: 424–430.

96.

Mix

Olsson

Correale

, et al. B cells expressing CD5 are increased in cerebrospinal fluid of patients with multiple sclerosis. Clin Exp Immunol 1990; 79: 21–27.

97.

Sádaba

Tzartos

Paíno

, et al. Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. J Neuroimmunol 2012; 247: 86–94.

98.

Muñoz

Sebal

Escudero

, et al. Main role of antibodies in demyelination and axonal damage in multiple sclerosis. Cell Mol Neurobiol 2022; 42: 1809–1827.

99.

Barnett

Prineas

. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458–468.

100.

Kirschning

Rutter

Uhlig

, et al. A sulfatide-reactive human monoclonal antibody obtained from a multiple sclerosis patient selectively binds to the surface of oligodendrocytes. J Neuroimmunol 1995; 56: 191–200.

101.

Massacesi

Vergelli

Zehetbauer

, et al. Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid-bound form. J Neurol Sci 1993; 119: 91–98.

102.

Krzalić

Nedeljković

Cvetković

, et al. Serum lipids and demyelination in experimental allergic encephalomyelitis induced by the increased encephalitogenicity of myelin basic protein given with galactocerebrospide. J Neuroimmunol 1989; 22: 193–199.

103.

Khang

Chi

Lee

. A study on demyelinating effect of galactocerebroside in experimental allergic encephalomyelitis. J Korean Med Sci 1988; 3: 89–98.

104.

Moore

Traugott

Farooq

, et al. Experimental autoimmune encephalomyelitis. Augmentation of demyelination by different myelin lipids. Lab Invest 1984; 51: 416–424.

105.

Raine

Traugott

. Chronic relapsing experimental autoimmune encephalomyelitis. Ultrastructure of the central nervous system of animals treated with combinations of myelin components. Lab Invest 1983; 48: 275–284.

106.

Raine

Traugott

Farooq

, et al. Augmentation of immune-mediated demyelination by lipid haptens. Lab Invest 1981; 45: 174–182.

107.

Souza

Diniz

de Lemos

, et al. Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: a 16-year non-concurrent cohort study. PLoS One 2020; 15: e0238476.

108.

Zaffaroni

. Treatment optimisation in multiple sclerosis. Neurol Sci 2005; 26(Suppl. 4): S187–S192.

109.

Gajofatto

Benedetti

. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases 2015; 3: 545–555.

110.

Magliozzi

Howell

Vora

, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130: 1089–1104.

111.

Serafini

Rosicarelli

Magliozzi

, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14: 164–174.

112.

Villar

García-Sánchez

Costa-Frossard

, et al. Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol 2012; 69: 191–197.

IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment

Abstract

Keywords

Introduction

Antibodies to lipids are a main characteristic of MS patients

Serum antibodies to PC are a diagnostic marker in MS

Antibodies to lipids are a prognosis marker

Antibodies to lipids are pathogenic

Antibodies to lipids predict the response to disease modifying treatments

Conclusions

Footnotes

Acknowledgements

Declarations

ORCID iDs

References